原始出處紀錄
Aldeyra 請求將 ADX-2191 IND 在 PVRL 的管轄權從眼科部門轉移至血液惡性腫瘤 2 部門,並撤回先前同意的 SPA 協議。監管路徑目前不明確,計劃中的試驗將無法啟動,且該計畫必須重新設計,這可能導致重大延遲、更高成本,或阻礙 NDA 重新提交和核准。
8-K false 0001341235 Massachusetts 0001341235 2026-11-09 2026-11-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2026 ALDEYRA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-36332 20-1968197 (State or other jurisdiction of incorporation) (Commission File No.) (IRS Employer Identification No.) 23 Bradford Street Concord , MA 01742 (Address of principal executive offices and zip code) Registrant’s telephone number, including area code: ( 781 ) 761-4904 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below